San Antonio Breast Cancer Symposium 2008: Zoledronic acid may have anti-tumour properties

Early results of the AZURE (Adjuvant Zoledronic Acid to Reduce Recurrence) trial suggest that zoledronic acid may have antitumor properties when combined with chemotherapy. Treatment was linked with a reduction in tumor size (20.5 mm vs. 30 mm), an increase in the complete response rate (10.9 percent vs. 5.8 percent) and a decrease in the number of patients requiring mastectomy (65.3 percent vs. 77.9 percent).

Dr Robert Coleman, speaking at the 2008 San Antonio Breast Cancer Symposium.

Category:

Science & Technology

Tags:

• evm
• ROBERT
• COLEMAN